StockData
Immunome Inc. logo

Immunome Inc. (IMNM) company profile

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$17.18−0.43 (-2.44%)

Close on Nov 17, 2026Market cap $1.95BP/E –Yield –

About Immunome

Pharmaceutical Preparations, SIC 2834

Immunome is a clinical-stage biotechnology company focused on discovering, designing, and developing targeted oncology therapeutics. Its pipeline centers on antibody-drug conjugates (ADCs), gamma secretase inhibitors, and radioligand therapies designed to treat solid tumors and hematologic malignancies. Primary investigational programs include varegacestat for desmoid tumors, IM-1021 for ROR1-expressing cancers such as B-cell lymphomas, and IM-3050 for fibroblast activation protein-positive solid tumors. In addition, the firm is advancing preclinical ADC candidates supported by its proprietary HC74 topoisomerase 1 inhibitor payload and linker technologies. The company's end users and customers encompass cancer patients, healthcare providers, and clinical trial participants seeking targeted oncologic treatments.

Immunome conducts clinical development on an international scale, running global registrational studies across clinical trial sites located in North America, Europe, Asia, and Australia. The company also utilizes external clinical-stage supply chains involving third-party diagnostic and radiotracer partners. The provided excerpt does not disclose the location of the company's corporate headquarters, operational facilities, or total employee headcount.

Summary of the business section of Immunome's latest annual report, written by StockData.

Company profile

Company

Legal name
Immunome Inc.
Headquarters
Bothell, WA
Address
18702 N. Creek Parkway, Suite 100 98011
Phone
(610) 321-3700
Employees
177, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
IMNM
Exchange
Nasdaq
IPO date
Oct 5, 2020
Shares outstanding
114M, Aug 6, 2026
Public float
$728.50M, Jun 30, 2025
Filer category
Non-accelerated filer
SEC CIK
1472012
CUSIP
45257U108
ISIN
US45257U1088
FIGI
BBG00BR93ZG8
Share class FIGI
BBG00BR94298
EIN
77-0694340

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Clay B. SiegallPresident and CEO, Director870,704
Jack HigginsChief Scientific Officer81,250
Kinney HornCHIEF BUSINESS OFFICER0
Max RosettChief Financial Officer101,287
Sandra G. StonemanCHIEF LEGAL OFFICER & GC43,805
Philip TsaiChief Technical Officer81,550
Robert LechleiderChief Medical Officer69,805
Isaac BarchasDirector92,211
Sandra M. SwainDirector–
Philip WagenheimDirector1,168,787
Carol SchaferDirector–
James P. BoylanDirector–
Jean Jacques BienaimeDirector43,415

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$7.68M$28.07M$2.77M$201–
FY2024$9.23M$8.41M$6.12M$99–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Clay Siegall, Ph.D.
President, Chief Executive Officer and Chairman of the Board
$735.00K$6.27M$661.50K$13.29K$7.68M-17%
Max Rosett
Chief Financial Officer
$472.50K$1.62M$278.80K$411.17K$2.79M–
Robert Lechleider, M.D.
Chief Medical Officer
$530.30K$1.90M$307.60K$12.19K$2.75M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 5, 2020
Offer price
$12.00
Securities offered
3,250,000
Gross proceeds
$39.00M
Exchange
Nasdaq
First trading day
Oct 2, 2020
First-day close
$13.45+12.1%
Lock-up ends (est.)
Mar 31, 2021

“The initial public offering price is $12.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 177 full-time employees, 133 of whom were engaged in research and development activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?